Scholars Central

Conference abstractPublished 25 May 2017

Relationship between cellular senescence and sorafenib efficacy in hepatocellular carcinoma

Authors: Leilei Niu, George G Chen, Paul B S Lai

Chinese University of Hong Kong, Hong Kong

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Statement of the Problem: Sorafenib is the only approved drug for the treatment of advanced hepatocellular carcinoma (HCC). However, its efficacy is largely limited by the emergence of primary and/or acquired resistance. Senescence-associated secretory phenotype (SASP) is now recognized as one of the darkest sides of senescence response because many factors that can promote tumor development are major components of SASP, such as IL6. SASP-mediated chemo-resistance has attracted increasing attention but never revealed in HCC. The purpose of this study is to investigate the effect of SASP on sorafenib resistance in HCC. Methods: The cytotoxicity of sorafenib in different HCC cell lines was determined by MTT assay. Cells were stained with senescenceassociated Ã?²-galactosidase, which is a typical biomarker of cellular senescence. Secreted IL6 proteins were measured using ELISA. Acquired sorafenib-resistant cells were constructed based on sensitive cells that treated were with increased concentrations of sorafenib. Findings: HCC cell lines exhibited different sensitivities to sorafenib. The cells with a strong SASP exhibited a low sensitivity to sorafenib. IL6 blocking in sorafenib-resistant HCC cells could significantly increase the cytotoxicity of sorafenib. A reduced cytotoxicity of sorafenib was detected when sorafenib-sensitive cells incubated with conditioned media from the acquired-resistant cells, in which IL6 level is higher than parent sensitive cells, accompanied by the stimulation of AKT phosphorylation. The reversal of sorafenib resistance in acquired-resistant cells could be achieved through IL6 blocking and AKT pathway inhibition. Conclusion: SASP can be used to account for sorafenib resistance. Combination therapy of sorafenib with IL6 blocking or AKT pathway inhibition can be considered as an effective strategy for HCC patient who is resistant to sorafenib.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Cancer Science & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalCancer Science & Therapy
  • SubjectOncology & Cancer
  • BylineArticles whose byline prints “Leilei Niu”
  • BylineArticles whose byline prints “George G Chen”
  • BylineArticles whose byline prints “Paul B S Lai”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels